company background image
TRDA logo

Entrada Therapeutics NasdaqGM:TRDA Stock Report

Last Price

US$7.62

Market Cap

US$271.1m

7D

-6.2%

1Y

-49.3%

Updated

22 May, 2025

Data

Company Financials +

Entrada Therapeutics, Inc.

NasdaqGM:TRDA Stock Report

Market Cap: US$271.1m

TRDA Stock Overview

A clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. More details

TRDA fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance2/6
Financial Health6/6
Dividends0/6

Rewards

Price-To-Earnings ratio (10.8x) is below the US market (17.8x)

Earnings have grown 49.3% per year over the past 5 years

Risk Analysis

Earnings are forecast to decline by an average of 36% per year for the next 3 years


Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

Entrada Therapeutics, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Entrada Therapeutics
Historical stock prices
Current Share PriceUS$7.62
52 Week HighUS$21.79
52 Week LowUS$7.10
Beta0.033
1 Month Change-12.51%
3 Month Change-41.56%
1 Year Change-49.27%
3 Year Change15.63%
5 Year Changen/a
Change since IPO-68.18%

Recent News & Updates

Lacklustre Performance Is Driving Entrada Therapeutics, Inc.'s (NASDAQ:TRDA) 27% Price Drop

Apr 04
Lacklustre Performance Is Driving Entrada Therapeutics, Inc.'s (NASDAQ:TRDA) 27% Price Drop

Results: Entrada Therapeutics, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts

Mar 02
Results: Entrada Therapeutics, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts

Entrada Therapeutics: Cash-Rich Innovator With Asymmetric Upside

Feb 19

Recent updates

Lacklustre Performance Is Driving Entrada Therapeutics, Inc.'s (NASDAQ:TRDA) 27% Price Drop

Apr 04
Lacklustre Performance Is Driving Entrada Therapeutics, Inc.'s (NASDAQ:TRDA) 27% Price Drop

Results: Entrada Therapeutics, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts

Mar 02
Results: Entrada Therapeutics, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts

Entrada Therapeutics: Cash-Rich Innovator With Asymmetric Upside

Feb 19

The Market Doesn't Like What It Sees From Entrada Therapeutics, Inc.'s (NASDAQ:TRDA) Revenues Yet As Shares Tumble 26%

Jan 11
The Market Doesn't Like What It Sees From Entrada Therapeutics, Inc.'s (NASDAQ:TRDA) Revenues Yet As Shares Tumble 26%

There Is A Reason Entrada Therapeutics, Inc.'s (NASDAQ:TRDA) Price Is Undemanding

Oct 17
There Is A Reason Entrada Therapeutics, Inc.'s (NASDAQ:TRDA) Price Is Undemanding

Analysts' Revenue Estimates For Entrada Therapeutics, Inc. (NASDAQ:TRDA) Are Surging Higher

Aug 23
Analysts' Revenue Estimates For Entrada Therapeutics, Inc. (NASDAQ:TRDA) Are Surging Higher

Entrada Therapeutics: A Complicated Tale

Jun 16

Entrada Therapeutics, Inc.'s (NASDAQ:TRDA) Shares Bounce 30% But Its Business Still Trails The Industry

May 29
Entrada Therapeutics, Inc.'s (NASDAQ:TRDA) Shares Bounce 30% But Its Business Still Trails The Industry

These Analysts Just Made A Massive Downgrade To Their Entrada Therapeutics, Inc. (NASDAQ:TRDA) EPS Forecasts

Mar 19
These Analysts Just Made A Massive Downgrade To Their Entrada Therapeutics, Inc. (NASDAQ:TRDA) EPS Forecasts

This Just In: Analysts Are Boosting Their Entrada Therapeutics, Inc. (NASDAQ:TRDA) Outlook for Next Year

Nov 09
This Just In: Analysts Are Boosting Their Entrada Therapeutics, Inc. (NASDAQ:TRDA) Outlook for Next Year

Need To Know: Analysts Are Much More Bullish On Entrada Therapeutics, Inc. (NASDAQ:TRDA)

May 26
Need To Know: Analysts Are Much More Bullish On Entrada Therapeutics, Inc. (NASDAQ:TRDA)

Earnings Miss: Entrada Therapeutics, Inc. Missed EPS And Analysts Are Revising Their Forecasts

May 14
Earnings Miss: Entrada Therapeutics, Inc. Missed EPS And Analysts Are Revising Their Forecasts

Will Entrada Therapeutics (NASDAQ:TRDA) Spend Its Cash Wisely?

Mar 08
Will Entrada Therapeutics (NASDAQ:TRDA) Spend Its Cash Wisely?

We're Not Very Worried About Entrada Therapeutics' (NASDAQ:TRDA) Cash Burn Rate

Sep 11
We're Not Very Worried About Entrada Therapeutics' (NASDAQ:TRDA) Cash Burn Rate

Entrada Therapeutics GAAP EPS of -$0.74 misses by $0.02

Aug 11

We're Not Very Worried About Entrada Therapeutics' (NASDAQ:TRDA) Cash Burn Rate

May 28
We're Not Very Worried About Entrada Therapeutics' (NASDAQ:TRDA) Cash Burn Rate

We Think Entrada Therapeutics (NASDAQ:TRDA) Can Afford To Drive Business Growth

Jan 31
We Think Entrada Therapeutics (NASDAQ:TRDA) Can Afford To Drive Business Growth

Shareholder Returns

TRDAUS BiotechsUS Market
7D-6.2%2.7%-1.4%
1Y-49.3%-13.0%10.5%

Return vs Industry: TRDA underperformed the US Biotechs industry which returned -14.9% over the past year.

Return vs Market: TRDA underperformed the US Market which returned 9.1% over the past year.

Price Volatility

Is TRDA's price volatile compared to industry and market?
TRDA volatility
TRDA Average Weekly Movement8.6%
Biotechs Industry Average Movement12.1%
Market Average Movement8.0%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market4.1%

Stable Share Price: TRDA has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: TRDA's weekly volatility (9%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2016183Dipal Doshiwww.entradatx.com

Entrada Therapeutics, Inc., a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. The company’s EEV platform develops products based on oligonucleotide, enzyme, and antibody-conjugated EEV peptides. Its therapeutic candidates, which include ENTR-601-44 that is in Phase 1 clinical trial for the treatment of Duchenne muscular dystrophy; and VX-670, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.

Entrada Therapeutics, Inc. Fundamentals Summary

How do Entrada Therapeutics's earnings and revenue compare to its market cap?
TRDA fundamental statistics
Market capUS$271.12m
Earnings (TTM)US$24.78m
Revenue (TTM)US$172.22m
10.8x
P/E Ratio
1.6x
P/S Ratio

Is TRDA overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
TRDA income statement (TTM)
RevenueUS$172.22m
Cost of RevenueUS$128.77m
Gross ProfitUS$43.45m
Other ExpensesUS$18.67m
EarningsUS$24.78m

Last Reported Earnings

Mar 31, 2025

Next Earnings Date

n/a

Earnings per share (EPS)0.70
Gross Margin25.23%
Net Profit Margin14.39%
Debt/Equity Ratio0%

How did TRDA perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/22 23:19
End of Day Share Price 2025/05/22 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Entrada Therapeutics, Inc. is covered by 9 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Chris ShibutaniGoldman Sachs
Raghuram SelvarajuH.C. Wainwright & Co.
Boobalan PachaiyappanH.C. Wainwright & Co.